Article Text

Download PDFPDF
144 Studying corticobasal syndrome across the UK via the BNSU
  1. Alyssa Costantini,
  2. Edwin Jabbari,
  3. Ruth Lamb,
  4. Marcia Darvell,
  5. John Woodside,
  6. Jon Rohrer,
  7. Andrew Lees,
  8. Huw Morris,
  9. on behalf of PROSPECT-UK & European CBS consortia
  1. The National Hospital for Neurology and Neurosurgery


Background There are a number of different causes of corticobasal syndrome (CBS) and we are recruiting CBS patients across the UK to the PROSPECT-UK study.

Objective To define patients with CBS and to define features that are helpful in determining the underlying pathological diagnosis.

Methods The RaDAR platform enables the recruitment of patients with CBS. Eligible patients are anonymously invited to contact the study team. Following informed consent, patients can participate remotely or be seen at their local study site. A subset of these patients undergo deep phenotyping, including CSF analysis for total Tau and Abeta.

Results We have established a cohort of 179 patients with CBS for future therapeutic, biomarkers and clinical studies. Mean recruitment is 5/month. The ABN RaDAR scheme has identified 58 CBS patients across the UK through 2018 so far, and we are liaising with consultants to recruit these patients. Deep phenotyping is underway – in patients with CSF analysis, 47% have an Alzheimer disease–like CSF profile highlighting the phenotypic diversity in this group. We are continuing to analyse other features of CBS.

Conclusions We are continuing to define the diverse pathological causes of CBS with a view to developing future disease modifying treatment trials.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.